Hidradenitis suppurativa: redirecting a life trajectory
Linked Article: Howells et al. Br J Dermatol 2021; 185:921–934.
Saved in:
Published in | British journal of dermatology (1951) Vol. 185; no. 5; p. 878 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
England
Oxford University Press
01.11.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Linked Article: Howells et al. Br J Dermatol 2021; 185:921–934. |
---|---|
Bibliography: | Conflicts of interest: J.H. is on the board of directors for the Hidradenitis Suppurativa Foundation, and is a speaker for AbbVie and consultant for Novartis. V.S. is on the board of directors for the Hidradenitis Suppurativa Foundation, and has served as an advisor, investigator and/or speaker for Sanofi Genzyme, Regeneron, AbbVie, Burt’s Bees, Dermira, Eli Lilly, Novartis, Pfizer, Incyte, Galderma, LEO Pharma, Sun Pharma, Menlo Therapeutics, gpskin, TARGET‐DERM, Kiniksa and Skin Actives Scientific. There was no financial transaction for the preparation of this manuscript. ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Commentary-1 |
ISSN: | 0007-0963 1365-2133 |
DOI: | 10.1111/bjd.20696 |